RxDoctor Payments Data

Vassilis Siomos, MD

Urology · Kalispell, MTNPI 1598907149

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (48.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Neotract Inc. accounts for 61.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,016 and has fallen 92.0% since, to $82 in 2025. That places this record below the midpoint for urology clinicians in MT, where the typical reported total is $1,996.

$1,532in general payments, 2019–2025

Across 22 payments — averaging $69.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$937
  • Astellas Pharma US Inc$198
  • Intuitive Surgical$198
  • Johnson & Johnson$82
  • Bayer$32
  • Dornier Medtech America, Inc$18
  • plus $69 from 5 others

What the payments were for

  • Travel & lodging$73948%
  • Food & beverage$60840%
  • Education$18512%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,532 in reported general payments places this provider in the 35th percentile of 45 urology providers in Montana.

See all urology providers in Montana

Medicare billing

Part B allowed, 2024
$123,259
Medicare patients
365
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron34$22,386
Silodosin116$6,028
Abiraterone Acetate19$2,490
Tamsulosin Hcl118$1,314
Finasteride81$1,303
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst43$852
Solifenacin Succinate24$472
Alfuzosin Hcl ErAlfuzosin Hcl39$419
Dutasteride11$304
Cephalexin64$282
Oxybutynin Chloride44$229
Effer-KPotassium Bicarbonate/Cit Ac11$184
Oxybutynin Chloride ErOxybutynin Chloride13$154
Oxycodone Hcl41$143
Ciprofloxacin Hcl25$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$198$22,38634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 45 urology providers in Montana.

Other urology in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →